ADVANCING NEUROLOGICAL DIAGNOSTICS

An exosome platform providing a noninvasive, inexpensive, and robust diagnostic tool.

 

 

OUR VISION

At NeuroDex, we envision a world where effective and preventative 
treatments for Alzheimer's exist. 

​​

The pharmaceutical industry has struggled over the past two decades to make headway in the Alzheimer's disease space due to a lack of inexpensive, noninvasive diagnostic tools. We want to bring the power of exosomes to the neurological diagnostic space - our technology has the potential to enable early detection, patient stratification, and disease monitoring,  which we believe will enable the first disease-modifying treatment for Alzheimer's. 
 

Our proprietary neuron-derived exosome isolation technology can be applied across a number of neurological indications. With our technology, a simple blood draw could allow physicians and researchers to open a window into the brain. 

 

THE 
NEURODEX 
ADVANTAGE

Our lead indication is Alzheimer's disease, a poorly understood disease affecting a third of the 65+ age population.

QUICK-TO-MARKET

 

Leveraging regulatory FDA framework for Lab- Developed-Tests creates a quick to-market-opportunity

PLATFORM TECHNOLOGY
​

Capturing neuron derived exosomes enables identification of diverse pathological aspects

SAMPLE FLEXIBILITY

 

Use of frozen samples enables utilization of retrospective biobanks

TARGETED

 

Our data demonstrates a robust and high precision platform

SYNERGISTIC

 

We offer an isolation platform that can be combined with different detection methodologies

TEAM EXPERTISE

 

We have industry and academic experience in public and private diagnostic companies

OUR TEAM

EREZ EITAN
CSO, Co-founder
Dr. Eitan was the first to study exosome...
ODED BIRAN
CEO, Co-founder
Oded is an experienced diagnostics execu...
CHRISTINA MENDONCA
Controller
Christina  is a Certified Public Account...
 

PUBLICATIONS FROM OUR TEAM

2019

Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging

L1CAM isolation in a large cohort of pre-symptomatic AD. [link]

2017

Plasma Extracellular Vesicles Enriched for Neuronal Origin: A Potential Window into Brain Pathologic Processes

L1CAM isolation description of the method. [link]

2017

In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and insulin signaling in plasma extracellular vesicles

L1CAM isolation to detect diet effect on insulin resistance. [link]

2017

Walking speed decline in older adults is associated with elevated pro-BDNF in plasma extracellular vesicles

L1CAM isolation for accelerated motor decline with age [link]

2016

Extracellular Vesicle-Associated Aβ Mediates Trans-Neuronal Bioenergetic and Ca2+-Handling Deficits in Alzheimer's Disease Models

L1CAM isolation from mice. [link]

2015

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study

L1CAM isolation and measurement of AD pathogenic proteins in AD and FTD. [link]

 

CONTACT

US

Please contact us with inquiries and questions at info@neurodex.co

 

© 2019 by NeuroDex. Made with 💜

  • Twitter Social Icon